

From: Nature Research <Nature@newsletter.nature.com>
Sent: Wednesday, 11 September 2019 10:32
To: Katja Herzog
Subject: EU-OPENSREEN: Small molecule screening and chemoproteomics open calls

[View this email in your browser](#)

Springer Nature continues its long standing tradition of providing the means for product manufacturers, service providers, publishers and other corporations to reach members of the scientific community who have opted-in to receive such messages. Springer Nature does not endorse any of the products or services advertised here.

The logo for eu openscreen features the word 'eu' in white lowercase letters, followed by a cluster of colored dots (orange, blue, and white) that transition into the word 'openscreen' in white lowercase letters.

EU-OPENSREEN integrates high-capacity screening platforms throughout Europe, which jointly use a rationally selected compound collection, comprising up to 140.000 commercial and proprietary compounds collected from European chemists.

Use EU-OPENSREEN ERIC's recently funded project EU-OPENSREEN-DRIVE to advance your research!

EU-OPENSREEN DRIVE launches its first calls - apply now:

Chemoproteomics Call

Promoting collaborative research on target identification and compound disposition studies.

Users from institutions within European member states and associated countries and up to one user from a non-European country will have the opportunity to access 7 advanced proteomics facilities across Europe. Through this open call, EU-OPENSSCREEN-DRIVE will select 3 user projects to access target-based and phenotype-based workflows, proteomics and related advanced mass spectrometry (MS) based technologies.

Deadline: September 30th, 2019

[Read more](#)

Small Molecule Screening Call

Offering transnational access to state-of-the-art high-throughput small molecule screening facilities for hit compound identification at 12 EU-OPENSSCREEN-DRIVE partner sites across Europe.

Through this open call, EU-OPENSSCREEN-DRIVE will select 12 user projects to access predefined screening technologies via 3 different tracks representing increasing levels of biological complexity ranging from individual isolated proteins all the way to organoids and engineered micro tissues.

Deadline: September 30th, 2019

[Read more](#)



Web: www.drive.eu-openscreen.eu

Email: drive@eu-openscreen.eu or office@eu-openscreen.eu



This project has received funding from the European Union's Horizon 2020 research and innovation programme under the grant agreement No. 823893

Please do not forget to follow our regular up-dates:



EU-OPENSREEN ERIC
Robert-Roessle-Str. 10
13125 Berlin, Germany

www.eu-openscreen.eu

© Nature

This email has been sent to REMOVED@springernature.com.

As a registered user of Nature Research websites, our databases indicates that you have opted-in to receive third-party emails. If you no longer wish to receive these marketing emails from Nature Research please [click here to unsubscribe](#).

If you wish to discontinue all email services from Nature Research please [click here to unsubscribe](#).

Springer Nature Limited is a company incorporated in England & Wales under company number 785998 & whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. Nature Research | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

SPRINGER NATURE

© 2019 Nature Research. Part of Springer Nature. All rights reserved.

0000014629